Functional intensified insulin therapy with short-acting insulin analog: effects on HbA1c and frequency of severe hypoglycemia an observational cohort study

To assess the effect of a particular insulin regimen called "functional insulin therapy" using a short-acting insulin analog on the risk of severe hypoglycemia and the HbA(1c) level among patients already under intensive insulin therapy. A cohort of 110 patients with type 1 diabetes receiv...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes & metabolism 2003-02, Vol.29 (1), p.53-57
Main Authors: HARTEMANN-HEURTIER, A, SACHON, C, MASSEBOEUF, N, CORSET, E, GRIMALDI, A
Format: Article
Language:English
Subjects:
Adult
Age of Onset
Biological and medical sciences
Blood Glucose - drug effects
Blood Glucose - metabolism
Cohort Studies
Diabetes Mellitus, Type 1 - blood
Diabetes Mellitus, Type 1 - drug therapy
Drug Administration Schedule
Epidemiologic Studies
Fasting
Female
General and cellular metabolism. Vitamins
Glycated Hemoglobin A - metabolism
Humans
Hypoglycemia - chemically induced
Hypoglycemia - epidemiology
Hypoglycemia - prevention & control
Hypoglycemic Agents - administration & dosage
Hypoglycemic Agents - therapeutic use
Insulin - administration & dosage
Insulin - adverse effects
Insulin - analogs & derivatives
Insulin - therapeutic use
Insulin Lispro
Insulin, Long-Acting - therapeutic use
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Postprandial Period
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To assess the effect of a particular insulin regimen called "functional insulin therapy" using a short-acting insulin analog on the risk of severe hypoglycemia and the HbA(1c) level among patients already under intensive insulin therapy. A cohort of 110 patients with type 1 diabetes receiving intensive insulin therapy with regular insulin for several years was followed during one year after initiation of functional insulin therapy (FIT) with a short-acting insulin analog. The glycemic control was assessed by the mean value of the last three HbA(1c) assays before the initiation of FIT and then by the mean of the following three. The number of severe hypoglycemic episodes/patient/year during the year preceding and the year following the initiation of FIT was recorded. The mean HbA(1c) level decreased on average by 0.7 percent during the 12-month study (p=0.0001) and the number of episodes of severe hypoglycemia fell to 75% of its previous level (p
ISSN:1262-3636
1878-1780
DOI:10.1016/S1262-3636(07)70007-1